E N D
1. Epilepsies, AEDs and Health Issues:The Love-Hate Relationship Janet Mifsud
Caritas Malta Epilepsy Association
Epilepsy Society of Malta
Vice President Europe IBE
Janet.mifsud@um.edu.mt
2.
3. ‘If it were not for the great variability between individuals, medicine would be a science not an art.’
Sir Walter Osler 1882
4. What do we know about epilepsy ?
5. Facts:
Epilepsy, affects as many as 6 million people in Europe, is a heterogeneous chronic disorder characterized by recurrent seizures:
which differ in nature
types of seizures
age at onset
aetiology
6. How is it treated?
8.
9. Yet…. Despite the large number of AEDs that suppress or prevent seizures are now available, so far, drug therapy available will only control the onset of seizures
There are no pharmacological treatments that cure epilepsy or modify the detrimental course of the disorder.
10. Why? What do drugs do? IMBALANCES ? DISEASE ? CORRECTION
11. How to decide?
12. users
13. How to decide: What is the problem?
14. How to decide: which drug?
15. Explicit knowledgecodified published transmissible
16. Which drug? Other factors….. The selection of the appropriate AED
also depends a variety of specific factors
age
underlying physiological conditions. etc
The prognosis and quality of life of a person with epilepsy varies considerably.
In addition, about 30% of patients, remain resistant to drug treatment.
This has major implications not only for other health issues, but also for independent living, education and employment, mobility, and personal relationships.
17. As there are no major differences in efficacy among first-line antiepileptic drugs, tolerability and long-term safety must be the paramount consideration in patients with epilepsy.
18. AEDs..when to start? Whether to treat first seizure is controversial
16-62% will recur within 5 years
Relapse rate might be reduced by antiepileptic drug treatment
Abnormal imaging, abnormal neurological exam, abnormal EEG or family history increase relapse risk
Quality of life issues are important
19. AEDs: how to? Correct therapeutic choice only after diagnosis
emphasis on monotherapy not polytherapy
care in special populations e.g. children, pregnant women
folic acid in females
keep epilepsy diary
keep same doctor
many months needed to adjust dose
Be aware of factors which may precipitate onset of seizures e.g. sleep deprivation, substance/ alcohol abuse, computer/TV games in children (?), stress
other treatment e.g. homeopathy?
regular discussions with parents/ teachers co-operations in - medication taking, correct observations
20. Choosing an AED Seizure type
Epilepsy Syndrome
Pharmacokinetics
Interactions
Other medical conditions
Efficacy
Adverse effects
Cost
21. Does the ideal AED exist? Effective in refractory patients
Low toxicity and no significant side effects
Interacts minimally with other drugs
Can easily be titrated
Works via a logical mechanism of action
Broad spectrum –no seizure aggravation
High efficacy, good tolerability
No contraindications
Friendly pharmacokinetics / once daily dosing
Availability of a friendly pediatric formulation
Availability of parenteral formulation
23. AEDs : matching drugs to patients Treatment failure is also often related to side effects or inability to tolerate the AED.
Several studies have shown that CNS, neuropsychological, systemic, and idiosyncratic adverse events lead to treatment failure in up to 40% of patients.
For those patients who remain on AED therapy, the side effects may contribute to a decreased quality of life.
24. Traditional AEDs For nearly 8 decades just 6 key AEDs.
Phenobarbital (Luminal) -1912
Phenytoin (Dilantin) -1938
Primidone (Mysoline) -1952
Benzodiazepines -1965
Ethosuximide (Tegretol) -1958
Carbamazepine (Tegretol) -1963
Valproic acid (Depakine)-1967
Associated with severe problems PK/PD
Narrow therapeutic indices ? more adverse effects
Extensive hepatic metabolism ? more drug interactions
Non linear kinetics ? large interindividual variation
25. New AEDs ‘the boring drugs’ Since 1993, several new AEDS promised improved tolerability with different safety and efficacy profiles
Felbamate (Felbatol)
Fosphenytoin (Cerebix)
Gabapentin (Neurontin)
Lamotrigine (Lamictal)
Levetiracetam (Keppra)
Oxcarbazepine (Trileptal)
Pregabalin (Lyrica)
Tiagabine (Gabitril)
Topiramate (Topamax)
Vigabatrin (Sabril)
Zonisamide (Zonegran)
Zebinex (Elsicarbezepine)
new formulations and chemical alterations of traditional AEDs
26. What did they promise? Broad spectrum of activity
Fewer side effects and better tolerability
Increased ease of use
Linear kinetics
Protein binding
Lack of drug interactions
Little liver metabolism and no toxic metabolites
Rapid titration and less frequent dosing schedules
No TDM needed
27. Which AED? Don’t forget drug interactions
28. Don’t’ forget drug interactions… ‘It is important for the clinician to recognize that treatment with AEDs, particularly the older enzyme inducing drugs …, may complicate the management of other co-morbid disorders. For example, cardiovascular disease and perhaps affective disorders (i.e. depression) may be commonly encountered in the patients with epilepsy of all ages, but particularly the elderly.
So don’t forget:
drugs used in the treatment of hypertension
drugs used in the treatment of lipid disorders
anticoagulants
drugs used in the treatment of depression
Check out Virepa course on AEDs
29. Generic AEDs..what to do?
Generic vs originator products
Excipents
30. Are AEDs forever? www.epilepsy.com/epilepsy/newsletter/jun09_AEDs
31. Why stop AEDs ? Side effects ……..
Drug interactions….
The bother of having to remember to take them, to pack them, and to renew them every month.
Even the idea of needing medicine and the associated stigma is philosophically distasteful to some people
EXPENSE
32. Discontinuing AEDs - when to consider it… Seizure freedom for ? 2 years implies overall >60% chance of successful withdrawal in some syndromes
Favorable factors
Control achieved easily on one drug at low dose
No previous unsuccessful attempts at withdrawal
Normal neurologic exam and EEG
Primary generalized seizures except JME
Consider relative risks/benefits (e.g., driving, pregnancy)
33. Yet, if they are stopped… There is the increased risk of having a seizure.
SUDEP
loss of driving license.
Impaired quality of life?
34. So…get the correct info.. http://www.ema.europa.eu
Advice from your national medicines authority